目的 探讨替比夫定治疗乙肝e抗原（HBeAg）阳性慢性乙型肝炎（CHB）患者72周的疗效及预测因素的分析。 方法 选择2007年9月－2012年9月符合入选标准的82例CHB患者接受替比夫定治疗72周，于治疗前基线、治疗后每3个月查丙氨酸氨基转移酶（ALT）、乙肝病毒DNA（HBV DNA）、乙肝病毒血清标志物，观察治疗期间累计生化学应答率、完全病毒学应答率(CVR)、HBeAg血清学转换率（SR）及耐药率，分析基线ALT水平[分为＜5 ULN（正常值检测下限）组及≥5 ULN组]、HBV DNA水平（分为＜107 copies/mL组及≥107 copies/mL组）、24周HBV DNA水平（＜3 log 10 copies/mL组及≥3 log 10 copies/mL组），预测72周CVR及SR。 结果 172周累计生化学应答率、CVR、SR、耐药率分别为86.6%、81.7%、42.7%、18.2%；2基线ALT≥5 ULN对72周SR有预测价值（χ2=5.651，P=0.017），HBV DNA＜107 copies/mL对CVR有预测价值（χ2=7.083，P=0.008）；324周HBV DNA＜103 copies/mL对72周CVR及SR均有预测价值（χ2=27.339，5.131；P=0.000，0.023）。 结论 替比夫定初治HBeAg阳性CHB患者疗效及安全性好，治疗24周HBV DNA＜103 copies/mL是72周疗效的最佳预测指标。
Whipple’s disease is a multisystemic disease caused by Tropheryma (T.) whipplei that primarily affects the gastrointestinal tract. In literature, T. whipplei can also cause pulmonary infections. The detection of T. whipplei depends on nucleic acid-based test. With the application of next-generation sequencing (NGS), cases with T. whipplei detected from respiratory tract samples by NGS are increasingly found but there is lack of recognized diagnostic criteria for these cases. Within the context, we propose a grading diagnostic scheme for the situation that T. whipplei is detected from respiratory tract samples, based on clinical experience and diagnostic thinking, and referring to the international classifications of invasive fungal infections. The scheme comprises five levels: confirmed, probable, possible, impossible, and excluded. There were 26 such cases from West China Hospital of Sichuan University and we used our diagnostic scheme to define probable in 6 cases, possible in 9 cases, impossible in 8 cases, and excluded in 3 cases. Based on this, we also propose specific suggestions for sample collection and testing, patient management, and further research directions. These recommendations are preliminary based on the existing cases from West China Hospital of Sichuan University and therefore needs to be verified, modified, optimized, and even reconstructed when more clinical evidence and further clinical studies become available.